| Nov 8 |
Upstream Bio reports Q3 revenue $607,000 vs $621,000 last year
|
| Nov 7 |
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Nov 5 |
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
|
| Nov 5 |
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
|
| Oct 17 |
Orbimed Advisors LLC Acquires New Stake in Upstream Bio Inc
|
| Oct 15 |
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
| Oct 14 |
Opening Day: Another trio of biotech IPOs make Friday debut
|
| Oct 11 |
Upstream Bio stock rallies 32% following upsized $255M IPO
|
| Oct 11 |
Upstream Bio prices IPO at $17 per share
|
| Oct 10 |
Upstream Bio Announces Pricing of Upsized Initial Public Offering
|
